Roles of Hepatitis B Virus Mutations in the Viral Reactivation After Immunosuppression Therapies

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2019 May 22

PMID 31109119

Citations 14

Authors

Jun Inoue

Takuya Nakamura

Atsushi Masamune

Affiliations

Soon will be listed here.

Abstract

Reactivation of hepatitis B virus (HBV) is a major problem in patients receiving chemotherapy for malignant diseases or immunosuppression therapies. It has been thought that a reduction in the immune responses might result in the reactivation of HBV replication from covalently closed circular DNA (cccDNA) residing in hepatocytes. However, not only the host's immune status, but also viral mutations have been reported to be associated with reactivation. Especially, several case reports about amino acid mutations in hepatitis B surface antigen (HBsAg) that escape from immune reactions have been reported, and recent reports showed that the frequencies of such mutations are higher than previously expected. In this review, we summarize the characteristics of viral mutations, including immune escape mutations in HBV-reactivated patients, and discuss their significance.

Citing Articles

An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable for Genomic Surveillance Within Clinical Diagnostic Settings.

Tshiabuila D, Choga W, San J, Maponga T, van Zyl G, Giandhari J Int J Mol Sci. 2024; 25(21).

PMID: 39519254 PMC: 11546910. DOI: 10.3390/ijms252111702.

Spontaneous reactivation of hepatitis B virus with multiple novel mutations in an elderly patient with resolved hepatitis B virus infection.

Sasaki T, Kakisaka K, Miyasaka A, Nishiya M, Yanagawa N, Kuroda H Clin J Gastroenterol. 2024; 17(4):683-690.

PMID: 38748198 DOI: 10.1007/s12328-024-01984-1.

Reactivation of hepatitis C virus caused by steroid monotherapy for sudden deafness.

Kaneko H, Ozono Y, Iwakiri H, Hatada H, Uchiyama N, Komaki Y Clin J Gastroenterol. 2024; 17(3):505-510.

PMID: 38587568 PMC: 11127820. DOI: 10.1007/s12328-024-01944-9.

An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable For Genomic Surveillance Within Clinical Diagnostic Settings.

Tshiabuila D, Choga W, James S, Maponga T, Preiser W, van Zyl G medRxiv. 2024; .

PMID: 38293032 PMC: 10827254. DOI: 10.1101/2024.01.19.24301519.

Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants.

Jilg N, Baumert T Hepatology. 2023; 78(3):702-705.

PMID: 37036194 PMC: 7615604. DOI: 10.1097/HEP.0000000000000400.

References

Steinberg J, Yeo W, Zhong S, Chan J, Tam J, Chan P . Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol. 2000; 60(3):249-55. View

Yeo W, Zhong S, Chan P, Ho W, Wong H, Chan A . Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat. 2000; 7(6):448-58. DOI: 10.1046/j.1365-2893.2000.00257.x. View

Marusawa H, Imoto S, Ueda Y, Chiba T . Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. J Gastroenterol. 2001; 36(9):633-6. DOI: 10.1007/s005350170049. View

Hou J, Wang Z, Cheng J, Lin Y, Lau G, Sun J . Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology. 2001; 34(5):1027-34. DOI: 10.1053/jhep.2001.28708. View

Kfoury Baz E, Zheng J, Mazuruk K, Van Le A, Peterson D . Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific "a" determinant conformation change and its application in diagnostic assays. Transfus Med. 2001; 11(5):355-62. DOI: 10.1046/j.1365-3148.2001.00323.x. View

Kakimi K, Lane T, Wieland S, Asensio V, Campbell I, Chisari F . Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med. 2001; 194(12):1755-66. PMC: 2193580. DOI: 10.1084/jem.194.12.1755. View

Dai M, Lu J, Chen Y, Perng C, Chao T . Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer. 2001; 92(11):2927-32. DOI: 10.1002/1097-0142(20011201)92:11<2927::aid-cncr10109>3.0.co;2-w. View

Chen P, Yao N, Wu C, Yang M, Lin Y, Hsiao L . Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. Transplantation. 2002; 74(2):182-8. DOI: 10.1097/00007890-200207270-00007. View

Westhoff T, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer J, Zidek W . Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood. 2003; 102(5):1930. DOI: 10.1182/blood-2003-05-1403. View

10.

Kim K, Lee K, Chang H, Ahn S, Tong S, Yoon Y . Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol. 2003; 71(3):367-75. DOI: 10.1002/jmv.10503. View

11.

Milich D, Liang T . Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003; 38(5):1075-86. DOI: 10.1053/jhep.2003.50453. View

12.

Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G . Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004; 126(7):1750-8. DOI: 10.1053/j.gastro.2004.03.018. View

13.

Zheng X, Weinberger K, Gehrke R, Isogawa M, Hilken G, Kemper T . Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology. 2004; 329(2):454-64. DOI: 10.1016/j.virol.2004.08.033. View

14.

Alexopoulou A, Dourakis S, Pandelidaki H, Archimandritis A, Karayiannis P . Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol. 2006; 78(8):1043-6. DOI: 10.1002/jmv.20660. View

15.

Alexopoulou A, Theodorou M, Dourakis S, Karayiannis P, Sagkana E, Papanikolopoulos K . Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations. J Viral Hepat. 2006; 13(9):591-6. DOI: 10.1111/j.1365-2893.2006.00728.x. View

16.

Moriyama T, Guilhot S, Klopchin K, Moss B, Pinkert C, Palmiter R . Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science. 1990; 248(4953):361-4. DOI: 10.1126/science.1691527. View

17.

Carman W, Zanetti A, Karayiannis P, Waters J, MANZILLO G, Tanzi E . Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990; 336(8711):325-9. DOI: 10.1016/0140-6736(90)91874-a. View

18.

Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M . Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006; 50(11):3867-74. PMC: 1635170. DOI: 10.1128/AAC.00239-06. View

19.

Hsu C, Yeh C, Chang M, Liaw Y . Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology. 2007; 132(2):543-50. DOI: 10.1053/j.gastro.2006.12.001. View

20.

Karatayli E, Karayalcin S, Karaaslan H, Kayhan H, Turkyilmaz A, Sahin F . A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007; 12(5):761-8. View